# Eagle Pharmaceuticals Inc. (EGRX)

Source: https://www.quantisnow.com/company/EGRX
Generated: 2026-11-19T23:45:26.191Z

- Ticker: EGRX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2014
- Website: eagleus.com

## About

Eagle Pharmaceuticals, Inc., a biotechnology pharmaceutical company, focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke, as well as to treat organophosphate exposure; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has a strategic collaboration with Tyme Technologies, Inc. to advance oral SM-88 for the treatment of patients with cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

## Latest EGRX news and filings

- 2026-10-30 17:05 UTC [Mergers & Acquisitions] [Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights Plan](https://www.quantisnow.com/insight/eagle-pharmaceuticals-board-extends-limited-duration-stockholder-rights-plan-6764984)
- 2026-08-26 14:00 UTC [Glancy Prongay Wolke & Rotter LLP, as Lead Counsel, Obtained $9.5 Million Settlement for Eagle Pharmaceuticals, Inc. Investors](https://www.quantisnow.com/insight/glancy-prongay-wolke-rotter-llp-as-lead-counsel-obtained-95-6695242)
- 2026-01-14 15:21 UTC [Eagle Pharmaceuticals Announces Divestiture of Barhemsys](https://www.quantisnow.com/insight/eagle-pharmaceuticals-announces-divestiture-of-barhemsys-6349131)
- 2025-10-30 10:50 UTC [Mergers & Acquisitions] [Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights Plan](https://www.quantisnow.com/insight/eagle-pharmaceuticals-board-extends-limited-duration-stockholder-rights-plan-6251010)
- 2025-10-21 20:05 UTC [Leadership Update] [Eagle Pharmaceuticals Announces Results of 2025 Annual Meeting of Stockholders](https://www.quantisnow.com/insight/eagle-pharmaceuticals-announces-results-of-2025-annual-meeting-of-stockholders-6240022)
- 2025-10-15 20:30 UTC [Eagle Pharmaceuticals Announces Availability of Unaudited Second Quarter 2025 Financial Statements](https://www.quantisnow.com/insight/eagle-pharmaceuticals-announces-availability-of-unaudited-second-quarter-2025-financial-6234158)
- 2025-10-06 23:30 UTC [Eagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial Statements](https://www.quantisnow.com/insight/eagle-pharmaceuticals-announces-availability-of-unaudited-first-quarter-2025-financial-6225195)
- 2025-09-17 20:43 UTC [Eagle Pharmaceuticals Announces Availability of Proxy Materials and Audited Financial Statements for the 2023 and 2024 Fiscal Years](https://www.quantisnow.com/insight/eagle-pharmaceuticals-announces-availability-of-proxy-materials-and-audited-financial-6204310)
- 2025-08-28 23:30 UTC [Leadership Update] [Eagle Pharmaceuticals to Appoint Abhinav Jain to its Board of Directors](https://www.quantisnow.com/insight/eagle-pharmaceuticals-to-appoint-abhinav-jain-to-its-board-of-6183029)
- 2025-08-18 20:30 UTC [Eagle Pharmaceuticals Announces 2025 Annual Meeting Date](https://www.quantisnow.com/insight/eagle-pharmaceuticals-announces-2025-annual-meeting-date-6170183)
- 2025-03-31 20:00 UTC [Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® Royalties](https://www.quantisnow.com/insight/eagle-pharmaceuticals-announces-69-million-agreement-to-monetize-bendeka-royalties-5966831)
- 2025-03-21 20:30 UTC [Mergers & Acquisitions] [Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan](https://www.quantisnow.com/insight/eagle-pharmaceuticals-announces-amendment-to-limited-duration-stockholder-rights-plan-5956062)
- 2025-01-24 21:08 UTC [SEC Form 15-12G filed by Eagle Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-eagle-pharmaceuticals-inc-5856643)
- 2024-12-10 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Eagle Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-eagle-pharmaceuticals-inc-5806458)
- 2024-12-02 21:17 UTC [SEC Form 8-K] [Eagle Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/eagle-pharmaceuticals-inc-filed-sec-form-8-k-entry-into-a-5796075)
- 2024-11-27 21:08 UTC [SEC Form RW filed by Eagle Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-rw-filed-by-eagle-pharmaceuticals-inc-5793475)
- 2024-11-27 21:08 UTC [SEC Form POS AM filed by Eagle Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-eagle-pharmaceuticals-inc-5793471)
- 2024-11-27 21:07 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Eagle Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-eagle-pharmaceuticals-inc-5793468)
- 2024-11-27 21:07 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Eagle Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-eagle-pharmaceuticals-inc-5793467)
- 2024-11-27 21:07 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Eagle Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-eagle-pharmaceuticals-inc-5793464)
- 2024-11-27 21:06 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Eagle Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-eagle-pharmaceuticals-inc-5793459)
- 2024-11-27 21:06 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Eagle Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-eagle-pharmaceuticals-inc-5793457)
- 2024-11-27 21:05 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Eagle Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-eagle-pharmaceuticals-inc-5793448)
- 2024-11-27 14:25 UTC [SEC Form 8-K] [Eagle Pharmaceuticals Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits](https://www.quantisnow.com/insight/eagle-pharmaceuticals-inc-filed-sec-form-8-k-changes-in-registrants-5793101)
- 2024-11-26 21:12 UTC [SEC Form 25 filed by Eagle Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-25-filed-by-eagle-pharmaceuticals-inc-5791991)
- 2024-11-20 00:59 UTC [SEC Form 3] [SEC Form 3 filed by new insider Krawtschuk Christopher](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-krawtschuk-christopher-5783898)
- 2024-11-15 22:19 UTC [SEC Form 8-K] [Eagle Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/eagle-pharmaceuticals-inc-filed-sec-form-8-k-notice-of-delisting-5779385)
- 2024-11-15 22:00 UTC [Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration](https://www.quantisnow.com/insight/eagle-announces-update-on-delisting-from-nasdaq-and-sec-deregistration-5779284)
- 2024-11-14 16:34 UTC [SEC Schedule 13G] [Amendment: SEC Form SC 13G/A filed by Eagle Pharmaceuticals Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-13ga-filed-by-eagle-pharmaceuticals-inc-5774098)
- 2024-11-13 13:30 UTC [SEC Form NT 10-Q filed by Eagle Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-nt-10-q-filed-by-eagle-pharmaceuticals-inc-5770229)
- 2024-11-12 12:08 UTC [SEC Form 8-K] [Eagle Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/eagle-pharmaceuticals-inc-filed-sec-form-8-k-leadership-update-regulation-5765188)
- 2024-11-12 12:00 UTC [Leadership Update] [Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer](https://www.quantisnow.com/insight/eagle-pharmaceuticals-appoints-christopher-krawtschuk-as-chief-financial-officer-5764492)
- 2024-11-05 21:32 UTC [SEC Schedule 13G] [Amendment: SEC Form SC 13G/A filed by Eagle Pharmaceuticals Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-13ga-filed-by-eagle-pharmaceuticals-inc-5753646)
- 2024-10-31 17:36 UTC [SEC Schedule 13G] [Amendment: SEC Form SC 13G/A filed by Eagle Pharmaceuticals Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-13ga-filed-by-eagle-pharmaceuticals-inc-5746193)
- 2024-10-31 12:50 UTC [SEC Form 8-K] [Eagle Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/eagle-pharmaceuticals-inc-filed-sec-form-8-k-entry-into-a-5745688)
- 2024-10-31 12:00 UTC [Mergers & Acquisitions] [Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan](https://www.quantisnow.com/insight/eagle-pharmaceuticals-adopts-limited-duration-stockholder-rights-plan-5745419)
- 2024-10-09 20:05 UTC [SEC Schedule 13G] [Amendment: SEC Form SC 13G/A filed by Eagle Pharmaceuticals Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-13ga-filed-by-eagle-pharmaceuticals-inc-5721086)
- 2024-10-08 16:42 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Eagle Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-eagle-pharmaceuticals-inc-5719521)
- 2024-10-02 13:00 UTC [SEC Form 8-K] [Eagle Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events](https://www.quantisnow.com/insight/eagle-pharmaceuticals-inc-filed-sec-form-8-k-results-of-operations-5711881)
- 2024-08-27 20:30 UTC [SEC Form 8-K] [Eagle Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/eagle-pharmaceuticals-inc-filed-sec-form-8-k-entry-into-a-5673534)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/EGRX
- Earnings history: https://www.quantisnow.com/earnings/EGRX
- Dividend history: https://www.quantisnow.com/dividends/EGRX
- Insider transactions: https://www.quantisnow.com/insiders/EGRX
- Options chain: https://www.quantisnow.com/options/EGRX
- SEC 8-K filings only: https://www.quantisnow.com/company/EGRX/8-k
- RSS and alerts for EGRX: https://www.quantisnow.com/docs/rss-feeds.md
